Monday, March 23, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Will the digital health bubble burst?

As a physician-turned investor, Dr. Sunny Kumar looks at the booming digital health market with the discernible eye of a clinician.

“The reality is private markets got a little bit exuberant in the last year for a variety of different reasons and we will likely see some degree of market correction,” Kumar says to Digital Health Business & Technology. “We are optimistic for the sector, as a whole, but are mindful of the fact that there may be some degree of correction, given the fact that not every single company can perform at the very, very top of expectations.”

Kumar and his fellow doctor-turned investor, Dr. Justin Norden, are partners at GSR Ventures, where they’ve led the investments for several digital health companies, including Medable, Alpha Medical and AppliedVR. Medable received a $304 million series D funding round in October, putting its total valuation at approximately $2.1 billion.

Source: Modern Healthcare

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

GLP-1 Drugs Have Moved Past Weight Loss. Medicine Has Not Fully Caught Up.

Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence

Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...

Read more

Join Our Newsletter!